Instantaneous Tumor Spray for Real-Time Surgical Guidance

用于实时手术指导的瞬时肿瘤喷雾

基本信息

项目摘要

Early stage ovarian cancer is typically asymptomatic. Undiagnosed until the disease has reached an advanced stage, the disease presents extensive intra-abdominal peritoneal metastases. Standard of care treatment includes either a surgical cytoreduction to remove tumor bulk, then platinum-based chemotherapy or primary neoadjuvant chemotherapy followed by interval cytoreduction after tumor shrinkage. Despite successful initial treatments, 80–90% of women with advanced cancer experience tumor recurrence. Surgical outcomes can vary considerably since some cancerous lesions are not visible to naked-eye surveillance or palpation, the only tools available to the surgeon in real-time. There is significant evidence that an extended disease-free period or even a cure are causally related to how much cancerous tissue is excised. A sensitive, specific, easy to visualize dye which precisely highlights small (< 5mm) and otherwise hidden lesions would better differentiate healthy from cancerous tissue, enable better informed surgical decisions and lead to better outcomes for ovarian cancer patients. In this collaboration between Molecular Targeting Technologies, Inc. and Weill Cornell Medical School we are developing a novel, tumor-specific agent for intraoperative near-infrared fluorescence imaging to guide ovarian cancer surgeries in real-time. In preliminary feasibility studies we have identified an optimized pH-sensitive near-infrared fluorogenic dye (CypH-11) which is non-fluorescent in normal tissues, but fluoresces immediately when sprayed onto cancer tissue, whose microenvironment is slightly acidic. We hypothesize that the cancer selective staining by CypH-11 will make the surgical debulking procedure precise and effective by locating normally unseen small and occult lesions, achieving a better surgical outcome. This approach could herald a paradigm shift in surgical oncology. In direct to Phase II SBIR studies we will scale-up synthesis and manufacture of CypH-11 and the final formulated vial in compliance with cGMP; perform preclinical optimization and validation of the CypH-11 formulation in a subcutaneous murine model and validate its sensitivity and specificity in an orthotopic model that simulates the clinical setting; and obtain pharmacokinetic, biodistribution and toxicity data to support an exploratory IND filing. The application will be submitted to the FDA anticipating a Phase 0 first-in-human study.
早期卵巢癌通常是无症状的。直到疾病发展到晚期才被诊断出来

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brian David Gray其他文献

Brian David Gray的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brian David Gray', 18)}}的其他基金

Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk
磷脂酰丝氨酸阻断纳米颗粒可改善抗血栓形成并降低出血风险
  • 批准号:
    10598788
  • 财政年份:
    2023
  • 资助金额:
    $ 99.94万
  • 项目类别:
Instantaneous Tumor Spray for Real-Time Surgical Guidance
用于实时手术指导的瞬时肿瘤喷雾
  • 批准号:
    10543617
  • 财政年份:
    2022
  • 资助金额:
    $ 99.94万
  • 项目类别:
Topical Drug Treatment of Cutaneous Leishmaniasis
皮肤利什曼病的局部药物治疗
  • 批准号:
    9383791
  • 财政年份:
    2017
  • 资助金额:
    $ 99.94万
  • 项目类别:
Multicolor Cell Membrane Profiling For Development And Disease
发育和疾病的多色细胞膜分析
  • 批准号:
    8589954
  • 财政年份:
    2013
  • 资助金额:
    $ 99.94万
  • 项目类别:
Anionic Phospholipid-Selective PET/SPECT Agent for Infection Imaging
用于感染成像的阴离子磷脂选择性 PET/SPECT 试剂
  • 批准号:
    8250164
  • 财政年份:
    2012
  • 资助金额:
    $ 99.94万
  • 项目类别:
Dual Modality Labels for Macro and Micro Detection and Quantification of Stem Cel
用于干细胞宏观和微观检测及定量的双模态标签
  • 批准号:
    7909750
  • 财政年份:
    2010
  • 资助金额:
    $ 99.94万
  • 项目类别:
Superior Near-IR Dyes for Bioimaging
用于生物成像的优质近红外染料
  • 批准号:
    7611638
  • 财政年份:
    2009
  • 资助金额:
    $ 99.94万
  • 项目类别:
Radiohybridization Imaging of HER2 Oncogene to Detect Breast Cancer
HER2 癌基因放射杂交成像检测乳腺癌
  • 批准号:
    7681555
  • 财政年份:
    2008
  • 资助金额:
    $ 99.94万
  • 项目类别:
Radiohybridization Imaging of HER2 Oncogene to Detect Breast Cancer
HER2 癌基因放射杂交成像检测乳腺癌
  • 批准号:
    7536308
  • 财政年份:
    2008
  • 资助金额:
    $ 99.94万
  • 项目类别:
Optimizing Tracers For Multicolor Neuronal Profiling
优化多色神经元分析示踪剂
  • 批准号:
    7418498
  • 财政年份:
    2004
  • 资助金额:
    $ 99.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了